FDA approves first contact lens to slow childhood nearsightedness

Eye
CooperVision's MiSight lens could also help reduce children’s risks of developing other eye problems later in life, according to the FDA, such as cataracts or detached retinas during adulthood. (Pixabay)

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

CooperVision’s MiSight lens is a soft, single-use and disposable contact, made to be discarded at the end of each day. 

A three-year clinical study showed the lens was able to slow the elongation of the eyeball from front to back by an average of 52% across annual check-ups—one of the main causes of myopia, as incoming images begin to come into focus at a point in front of the retina, instead of precisely on it.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“We can’t overstate the importance and potential impact of this landmark decision on children’s vision, especially considering the rise in myopia’s severity and prevalence in the U.S. and worldwide,” CooperVision President Daniel McBride said in a statement. “Eye care professionals who embrace this breakthrough approach will improve the quality of life and eye health for so many children.” 

RELATED: J&J’s antihistamine-eluting contact lenses clear phase 3 allergy studies

The MiSight lens could also ultimately reduce children’s risks of developing other eye problems, according to Malvina Eydelman, director of the FDA office tasked with evaluating ophthalmic devices. Children who develop severe myopia are more likely to be susceptible to cataracts or a detached retina during adulthood.

The three-year clinical trial, which enrolled 135 children, also demonstrated 59% slower myopia progression through the optics measurement of average cycloplegic spherical equivalent, compared to a control group of children wearing conventional, one-day soft contact lenses. CooperVision reported that it received encouraging study results through years four and five, and that some participants are still wearing the lens into their late teens.

RELATED: Johnson & Johnson rolls out its light-adaptive contact lenses with Transitions tech

When placed on the eye, part of the lens works to improve distance vision by correcting the refractive error similar to a standard contact. The MiSight lens also features concentric rings placed around the periphery, which split off light and focus it in front of the retina, to help reduce the stimulus believed to drive the progression of nearsightedness.

CooperVision plans to launch the lens in the U.S. starting in March 2020. It is already available in Canada, the U.K., Spain and Australia, for children of varying ages.

Suggested Articles

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.